Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.

about

Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration.

P2860

Q34989562-DF1C7AEF-197C-4738-AE27-590F8441D18C Q41925040-D421634A-2E80-448C-BE04-F70D0A1473DF

P2860

Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.

Item

http://www.wikidata.org/entity/Q42144314

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.

@en

Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.

@nl

type

Item

label

Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.

@en

Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.

@nl

prefLabel

Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.

@en

Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.

@nl

P1476

Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.

@en

P2093

Dimitris Mavroudis

http://www.w3.org/2001/XMLSchema#string

Lambros Vamvakas

http://www.w3.org/2001/XMLSchema#string

Nikolaos Androulakis

http://www.w3.org/2001/XMLSchema#string

Vassilis Georgoulias

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibition and renal thrombotic microangiopathy

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

Nephrotic syndrome after bevacizumab: case report and literature review.

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Preeclampsia and angiogenic imbalance.

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

P304

368-371

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1159/000321630

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Emmanouil Saloustros

P577

2010-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51093362

http://www.w3.org/2001/XMLSchema#string

P698

21537380

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

3085070

http://www.w3.org/2001/XMLSchema#string

Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.

about

P2860

P2860

Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932